Testolone 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Usage

1. Complete pre-cycle blood work covering total testosterone, LH, FSH, and a liver panel — this is the benchmark for your PCT recovery assessment.
2. Begin at exactly one tablet (10mg) per day, taken in the morning with food to reduce the chance of nausea during the assessment phase.
3. After 14 days at 10mg, evaluate your response — sleep quality, strength trajectory, and any aggression or mood changes — before deciding whether to advance to 15mg.
4. For mass-phase escalation, take 1.5 to 2 tablets (15–20mg) each morning; do not split the dose across morning and evening, as RAD-140's half-life of approximately 16–20 hours supports once-daily administration.
5. Do not exceed 8 weeks of continuous use; longer cycles increase suppression depth without proportionate additional anabolic benefit.
6. Begin SERM-based PCT within 48–72 hours of your final RAD-140 tablet, and repeat blood work four weeks into PCT to confirm testosterone recovery before planning any subsequent cycle.

Warnings

Frequently asked questions

Why is RAD-140 considered the strongest SARM for muscle mass?

RAD-140 holds the highest published anabolic-to-androgenic ratio of any characterised SARM — approximately 90:1 in preclinical models, compared to MK-2866's ratio of around 3:1. This means RAD-140 activates androgen receptors in skeletal muscle far more aggressively per milligram, producing measurable lean mass accumulation at doses as low as 10mg per day. Its potency is the primary reason experienced users treat cycle length and PCT as non-negotiable, not optional.

What side effects does Testolone (RAD-140) cause at a 10mg dose?

At 10mg per day, RAD-140 commonly causes mild-to-moderate testosterone suppression over a 6–8 week cycle, which typically resolves with a standard SERM-based PCT. Some users report elevated aggression, sleep disruption, or mild lipid shifts. Androgenic effects such as hair acceleration are possible in genetically predisposed individuals. Hepatotoxicity risk is lower than with 17-alpha-alkylated oral steroids, but liver enzyme monitoring is still advisable for cycles exceeding four weeks.

Do you need a PCT after a RAD-140 cycle, and what should it include?

Yes — RAD-140 is sufficiently suppressive that PCT is required for the majority of users, particularly at doses of 15mg or above or cycles longer than six weeks. A standard protocol uses Nolvadex (tamoxifen) at 20mg per day for four weeks, or Clomid (clomiphene) at 25–50mg per day for the same duration. Blood work measuring LH, FSH, and total testosterone before and after the cycle is the most reliable way to confirm recovery.

What makes the 10mg tablet format ideal for a first RAD-140 cycle?

The 10mg per tablet concentration matches the recommended starting dose exactly, eliminating the measurement errors associated with liquid SARMs and the inaccuracy of tablet splitting. For a first RAD-140 cycle, beginning at one tablet per day for two weeks before assessing progress is the most controlled approach. Elbrus Pharmaceuticals' HPLC-verified tablets ensure each dose is accurate — critical when working with a compound this potent at relatively small absolute quantities.

How does RAD-140 from Elbrus Pharmaceuticals compare to liquid RAD-140 products in terms of dosing accuracy?

Pressed tablets with a declared HPLC-verified concentration offer superior dosing consistency compared to liquid suspensions, where settling, temperature variation, and pipette errors can introduce meaningful variance. Elbrus Pharmaceuticals' 10mg RAD-140 tablets are batch-tested at the finished-product stage using HPLC, confirming actual API content rather than relying on raw material certificates. For a compound where the therapeutic window between an effective dose and an overly suppressive one is narrow, tablet format is a practical safety advantage. (2) angle_used

Manufacturer

The production philosophy behind Elbrus Pharmaceuticals' RAD-140 tablet line is most clearly understood not from its testing procedures in isolation, but from the sequence in which those procedures are applied — and why that sequence is treated as non-negotiable. Elbrus positions its analytical framework around a single structural argument: for a compound with an anabolic potency as concentrated as RAD-140, the margin between a correctly dosed tablet and a materially over- or under-dosed one is narrow enough to carry real consequences for the user. That argument led the brand to establish two independent release gates — finished-product HPLC potency verification confirming declared 10mg API content, and LAL (Limulus Amebocyte Lysate) endotoxin screening for microbiological safety — neither of which can be bypassed or substituted by raw material supplier documentation. The Elbrus RAD-140 line is produced under ISO-aligned GMP conditions, with environmental monitoring records maintained throughout the compression and blister-sealing stages. Batch-level documentation is assigned at the point of release clearance, not retrospectively — meaning the lot number attached to a blister pack corresponds to a specific analytical record, not a generalised compliance statement. This approach reflects the founding rationale Elbrus articulated when entering the research-compound market: that the market's credibility problem was traceable to the gap between what manufacturers claimed and what they could document, and that closing that gap required treating analytical evidence as the release criterion rather than a supplementary assurance.